Oxygen Biotherapeutics, Inc. has partnered with PPD to conduct its Phase IIb trial, STOP-TBI (Safety and Tolerability of Oxycyte in Patients with Severe non-Penetrating Traumatic Brain Injury). The trial will evaluate the safety and tolerability of a single administration of Oxycyte in patients with severe non-penetrating traumatic brain injury. The secondary objective is to assess the potential of Oxycyte in improving the severity of TBI.   Dr. Timothy Bradshaw, executive vice president of Drug...